- New York Abilify Lawsuit Lawyer
- New York Actos Lawsuit Lawyer
- New York Benicar Lawsuit Lawyer
- New York Invokana Lawsuit Lawyer
- New York Januvia Lawsuit Lawyer
- New York Onglyza and Kombiglyze XR Lawsuit Lawyer
- New York Opioids Lawsuit Lawyer
- New York Pradaxa Lawsuit Lawyer
- New York Risperdal Lawsuit Lawyer
- New York Talcum Powder Lawsuit Lawyer
- New York Taxotere Lawsuit Lawyer
- New York Victoza Lawsuit Lawyer
- New York Vioxx Lawsuit Lawyer
- New York Xarelto Lawsuit Lawyer
- New York Zostavax Lawsuit Lawyer
- MAIN Defective Drugs & Devices
New York Abilify Lawsuit Lawyer
Abilify (aripiprazole), is classified as a second generation atypical antipsychotic medication. It is intended to treat mental conditions and mood disorders such as Tourette’s, bipolar disorder, schizophrenia, and irritability associated with autistic disorders. Abilify is intended to decrease depressive thoughts, tics, hallucinations, mood swings, and disorganized thinking and was first approved by the U.S. Food and Drug Administration (FDA) in 2002.
The last thing you need when you are prescribed medication to treat a mental condition is to find out the medication that is supposed to help you get better, is causing you to act abnormal in potentially harmful ways. If you are already battling a mood disorder adding an unexpected side effect does not help your ability to cope on a day-to-day basis. We understand. Sobo & Sobo L.L.P. has provided unsurpassed legal services and won countless personal injury settlements for thousands of New York victims and we are here to help you.
The Case Against Ability
Made by Otsuka Pharmaceutical as well as Bristol-Myers Squibb, there are over 1,600 lawsuits and counting filed in federal courts alleging the drug can cause users to participate in compulsive sex, shopping, eating and gambling. Most of the lawsuits relate to Abilify causing the patient to gamble compulsively.
Both Big Pharma Companies Have Been Accused Of:
- Alleged negligence in designing Abilify
- Hiding evidence that showed the drug increases the risk of addictive behavior
- Failure to warn doctors and consumers of the connection between Abilify and compulsive behaviors
The key issue here is that the person taking the drug compulsively performs a certain action even if it is causing him or her social, financial and personal injury. It appears that Abilify affects the feel good chemical that exists in our brains, dopamine. Dopamine functions as a neurotransmitter and includes several paths to the brain, one that plays a major role in the motivational component of reward- motivated behaviour. Gambling, eating, shopping, etc., are reward-motivated behaviors.
In 2016, the FDA issued a warning that it had reviewed a number of cases linking Ability to compulsive gambling, shopping, eating, sexual interactions and impulse control issues. The cases indicated that soon after the patient started taking the drug their compulsive behaviour manifested and when the drug was stopped to allow the patient to switch to another drug, the compulsive behavior stopped.
Of interest is the fact that European Abilify labels included warnings about addictive behavior beginning in 2012, and Canada started requiring the warning in 2015 to date the US does not require warning labels.
Side Effects Of Abilify Include:
- Blurred vision
- Weight gain
- Hyperglycemia – high blood sugar
- Suicidal thoughts (in pre-teens)
- Excessive saliva production
- Upper respiratory illness
- Low blood pressure
- Low blood count
- Tics – involuntary, repetitive movements
- Difficulty swallowing
- Strokes – in older patients
- Neuroleptic malignant syndrome – life-threatening reaction characterized by fever, muscular rigidity, altered mental status, and autonomic dysfunction
- Unregulated body temperature
Often Prescribed for Off-label Purposes
Court records indicate the drug makers did not properly test the drug, overrated its benefits and actively encouraged doctors to use Abilify for off-label purposes not approved by the FDA.
Bristol-Myers Squibb paid a $515 million penalty in 2005 settling claims that they marketed Abilify for off-label use to elderly patients and children. Otsuka Pharmaceutical paid $4 million to settle similar claims for marketing off-label use to child psychiatrists and nursing homes.
Bristol-Myers Squibb also paid $19.5 million in 2016 to settle claims that they minimized the risks of Abilify, misrepresented clinical trial data and illegally promoted the drug for off-label purposes. They paid a further $30 million for illegally paying doctors to prescribe Abilify.
Off-label Purposes – Abilify is NOT intended to treat:
- OCD – obsessive compulsive disorder
- PTSD – post traumatic stress disorder
- Eating disorders
- Dementia (may increase the risk of death in dementia patients)
How Sobo & Sobo Can Help
The attorneys at Sobo & Sobo are personal injury law leaders in the Hudson Valley community. We will put our experience to use during your initial consultation as we listen to your story and help you make informed decisions about how to proceed with your defective drug case.
Types Of Damages That May Be Recovered Include:
- Past medical costs to treat addiction
- Future medical expenses to treat addiction.
- Past mental pain and suffering caused by addiction
- Future mental pain and suffering caused by addiction
- Loss of wages
- Gambling losses
- Other economic losses sustained due to compulsive behavior
- Punitive damages if the case warrants it
Take the time to learn about your legal rights by calling Sobo & Sobo at 855-468-7626 as soon as possible. Our prompt action, in partnership with you, could make a difference in the outcome of your case. We would be honored to hear your story and look forward to taking the next step toward Winning Together.